DOCSLIB.ORG

Brain RAS: Hypertension and Beyond

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

International Journal of Hypertension Brain RAS: Hypertension and Beyond Guest Editors: Marc de Gasparo, Robert C. Speth, Ovidiu C. Baltatu, and Patrick Vanderheyden Brain RAS: Hypertension and Beyond International Journal of Hypertension Brain RAS: Hypertension and Beyond Guest Editors: Marc de Gasparo, Robert C. Speth, Ovidiu C. Baltatu, and Patrick Vanderheyden Copyright © 2013 Hindawi Publishing Corporation. All rights reserved. This is a special issue published in “International Journal of Hypertension.” All articles are open access articles distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Editorial Board Maciej Banach, Poland Kazuomi Kario, Japan Gary Lee Schwartz, USA Vecihi Batuman, USA Tomohiro Katsuya, Japan Joseph I. Shapiro, USA Claudio Borghi, Italy Marcel Lebel, Canada Helmy M. Siragy, USA Vito M. Campese, USA Kiyoshi Matsumura, Japan Masayoshi Soma, Japan Francesco Cappuccio, UK Albert Mimran, France Thomas Unger, Germany Oscar A. Carretero, USA Shawna D. Nesbitt, USA Franco Veglio, Italy Santina Cottone, Italy G. Parati, Italy M. Volpe, Italy Daniel Duprez, USA Stefano Perlini, Italy B. Waeber, Switzerland Csaba Farsang, Hungary Roberto Pontremoli, Italy Donna Wang, USA John M. Flack, USA Hiromi Rakugi, Japan M. R. Weir, USA J. Hall, USA Giuseppe Schillaci, Italy Yoram Yagil, Israel Junichiro Hashimoto, Japan Markus Schlaich, Australia Xiao-Ping Yang, USA Contents Brain RAS: Hypertension and Beyond,MarcdeGasparo,RobertC.Speth,OvidiuC.Baltatu, and Patrick Vanderheyden Volume 2013, Article ID 157180, 3 pages Immunohistochemical Localization of AT1a,AT1b, and AT2 Angiotensin II Receptor Subtypes in the Rat Adrenal, Pituitary, and Brain with a Perspective Commentary, Courtney Premer, Courtney Lamondin, Ann Mitzey, Robert C. Speth, and Mark S. Brownfield Volume 2013, Article ID 175428, 22 pages Distinct Molecular Effects of Angiotensin II and Angiotensin III in Rat Astrocytes, Michelle A. Clark, Chinh Nguyen, and Hieu Tran Volume 2013, Article ID 782861, 8 pages The Brain-Heart Connection: Frontal Cortex and Left Ventricle Angiotensinase Activities in Control and Captopril-Treated Hypertensive Rats—A Bilateral Study, Ana B. Segarra, Isabel Prieto, Inmaculada Banegas, Ana B. Villarejo, Rosemary Wangensteen, Marc de Gasparo, Francisco Vives, and Manuel Ram´ırez-Sanchez´ Volume 2013, Article ID 156179, 7 pages Elevated Blood Pressure in the Acute Phase of Stroke and the Role of Angiotensin Receptor Blockers, Simona Lattanzi, Mauro Silvestrini, and Leandro Provinciali Volume 2013, Article ID 941783, 8 pages AT2 Receptor-Interacting Proteins ATIPs in the Brain, Sylvie Rodrigues-Ferreira, Erwann le Rouzic, Traci Pawlowski, Anand Srivastava, Florence Margottin-Goguet, and Clara Nahmias Volume 2013, Article ID 513047, 6 pages The Brain Renin-Angiotensin System and Mitochondrial Function: Influence on Blood Pressure and Baroreflex in Transgenic Rat Strains, Manisha Nautiyal, Amy C. Arnold, Mark C. Chappell, and Debra I. Diz Volume 2013, Article ID 136028, 8 pages The Angiotensin-Melatonin Axis, Luciana A. Campos, Jose Cipolla-Neto, Fernanda G. Amaral, Lisete C. Michelini, Michael Bader, and Ovidiu C. Baltatu Volume 2013, Article ID 521783, 7 pages RAS in Pregnancy and Preeclampsia and Eclampsia, M. Rodriguez, J. Moreno, and J. Hasbun Volume 2012, Article ID 739274, 6 pages The Angiotensin II Type 2 Receptor in Brain Functions: An Update, Marie-Odile Guimond and Nicole Gallo-Payet Volume 2012, Article ID 351758, 18 pages The Prorenin and (Pro)renin Receptor: New Players in the Brain Renin-Angiotensin System?, Wencheng Li, Hua Peng, Dale M. Seth, and Yumei Feng Volume 2012, Article ID 290635, 8 pages Upregulation of the Renin-Angiotensin-Aldosterone-Ouabain System in the Brain Is the Core Mechanism in the Genesis of All Types of Hypertension, Hakuo Takahashi Volume 2012, Article ID 242786, 10 pages Roles of Brain Angiotensin II in Cognitive Function and Dementia, Masaki Mogi, Jun Iwanami, and Masatsugu Horiuchi Volume 2012, Article ID 169649, 7 pages Discovery of Inhibitors of Insulin-Regulated Aminopeptidase as Cognitive Enhancers, Hanna Andersson and Mathias Hallberg Volume 2012, Article ID 789671, 18 pages Renin-Angiotensin System and Sympathetic Neurotransmitter Release in the Central Nervous System of Hypertension, Kazushi Tsuda Volume 2012, Article ID 474870, 11 pages Cardiac-Autonomic Imbalance and Baroreflex Dysfunction in the Renovascular Angiotensin-Dependent Hypertensive Mouse, Bianca P. Campagnaro, Agata L. Gava, Silvana S. Meyrelles, and Elisardo C. Vasquez Volume 2012, Article ID 968123, 9 pages Hindawi Publishing Corporation International Journal of Hypertension Volume 2013, Article ID 157180, 3 pages http://dx.doi.org/10.1155/2013/157180 Editorial Brain RAS: Hypertension and Beyond Marc de Gasparo,1 Robert C. Speth,2 Ovidiu C. Baltatu,3 and Patrick Vanderheyden4 1 Unit of Physiology, University of Jaen,´ 23071 Jaen,´ Spain 2 Department of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL 33328-2018, USA 3 Center of Biomedical Engineering, University Camilo Castelo Branco, 12247-004 Sao˜ Jose´ dos Campos, SP, Brazil 4 Department of Molecular and Biochemical Pharmacology, Vrije Universiteit Brussel, 1050 Brussels, Belgium Correspondence should be addressed to Marc de Gasparo; m.de [email protected] Received 25 February 2013; Accepted 25 February 2013 Copyright © 2013 Marc de Gasparo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Cardiac output and vascular resistance are the cornerstones of paraventricular, and solitary tract nucleus of the rat brain as blood pressure regulation, which is achieved through neural, well as in the pituitary and adrenal. humoral, and local tissue factors. Ang II formation in the pineal gland and glial cells The sympathetic nervous system (SNS) and the renin- appears to depend on alternative pathways including chy- angiotensin system (RAS) play a major role in the control mase (L. A. Campos et al.). One possibility might be that of blood pressure. Angiotensins act as endocrine, paracrine, the prorenin receptor (PRR) binds prorenin or renin from and autocrine regulators. The peripheral physiological and circulationtoformAngIandchymasetoformAngII. pathophysiological actions of the RAS are well established. The brain PRR appears to initiate the brain angiotensin The existence and functional relevance of the RAS inthe peptide formation (W. Li et al.). Indeed, PRR is expressed brainisincreasinglyrecognizedasamajorregulatorofthe ubiquitously in the brain with the highest expression levels cardiovascular (CV) system and a significant drug target in the pituitary and frontal lobe. Recent findings indicate that for antihypertensive and other CV therapeutics. All the PRR has RAS independent roles associated with the vacuolar constituentsoftheRASoccurinthebrainandparticipate proton-ATPase and the Wnt signaling pathways (W.Li et al.). in the regulation of blood pressure through sympathetic PRRinthebraincouldplayapivotalroleinneuralregulation activation and vasopressin release. In addition, an intercon- of blood pressure and body fluid homeostasis. nection between neurotransmitters and the brain RAS affects In addition, AT4/IRAP and Mas receptors are also present behavior and neurological diseases, for example, Parkinson’s, in the brain. Aminopeptidases (and other angiotensins and Alzheimer’s diseases. Moreover, the clinical efficacy of degrading enzymes, e.g., ACE2 and endopeptidase), which renin and ACE inhibitors and angiotensin receptor blockers form fragments such as Ang III, Ang IV, Ang 2–10, Ang 1–9, (ARBs) and the presence of their targets in the brain illustrate and Ang 1–7, are also the topic of several reports (A. B. Segarra the synergistic interaction between brain and peripheral RAS. et al.; M. A. Clark et al.). This special issue illustrates some aspects of the brain RAS Formation of Ang III in the brain may promote hyper- pathway and function including its effect on the circadian tension while Ang IV, which inhibits vasopressinase activity rhythm of blood pressure. and may have a therapeutic value for cognitive function in the The RAS has been described in the brain. Using sub- brain. type specific antibodies, C. Premer et al. observed selective There is still a debate regarding the relative importance of expression of AT1a, AT1b, and AT2 receptor subtypes in Ang II and Ang III in the brain. Using astrocytes in culture neurons and glia in a large number of brain regions including andaninhibitorofaminopeptidaseAtopreventconversion the subfornical organ, median eminence, area postrema, of Ang II to Ang III, M. A. Clark et al. demonstrate that both 2 International Journal of Hypertension Ang II and Ang III induce phosphorylation of MAPK and and dementia (M. Mogi et al.). In addition, the AT2 receptor JNK and stimulate astrocyte growth equipotently. appears to play a role in metabolic syndrome as it regulates Ang IV binds to the AT4 receptor. While the AT4 receptor appetite and increases glucose uptake. Finally, it is proposed has been convincingly shown to be the insulin-regulated that the AT2 receptor behaves like a gate keeper of cellular and aminopeptidase IRAP, (also known as vasopressinase and tissue homeostasis (M. O. Guimond
Recommended publications
  • Emerging Pharmacological Strategies for the Treatment

    Emerging Pharmacological Strategies for the Treatment

    Emerging pharmacological strategies for the treatment of fibromyalgia LAWSON, Kim Available from Sheffield Hallam University Research Archive (SHURA) at: http://shura.shu.ac.uk/15300/ This document is the author deposited version. You are advised to consult the publisher's version if you wish to cite from it. Published version LAWSON, Kim (2017). Emerging pharmacological strategies for the treatment of fibromyalgia. World Journal of Pharmacology, 6 (1), 1-10. Repository use policy Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in SHURA to facilitate their private study or for non- commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain. Sheffield Hallam University Research Archive http://shura.shu.ac.uk World Journal of WJ P Pharmacology Submit a Manuscript: http://www.wjgnet.com/esps/ World J Pharmacol 207 March 9; 6(): -0 DOI: 0.5497/wjp.v6.i. ISSN 2220-392 (online) MINIREVIEWS Emerging pharmacological strategies for the treatment of ibromyalgia Kim Lawson Kim Lawson, Department of Biosciences and Chemistry, Bio­ presenting with a complex of symptoms dominated by molecular Sciences Research Centre, Shefield Hallam University, chronic widespread pain associated with the existence of a Faculty of Health and Wellbeing, Sheffield S1 1WB, United range of co-morbidities, such as fatigue, sleep disturbance, Kingdom cognitive impairment, anxiety and depression. Current treatments include drugs that target serotonin and nor- Author contributions: Lawson K researched the materials for the article and wrote the manuscript.
  • Rodgers 693..696

    Rodgers 693..696

    Copyright #ERS Journals Ltd 1999 Eur Respir J 1999; 14: 693±696 European Respiratory Journal Printed in UK ± all rights reserved ISSN 0903-1936 The effect of topical benzamil and amiloride on nasal potential difference in cystic fibrosis H.C. Rodgers, A.J. Knox The effect of topical benzamil and amiloride on nasal potential difference in cystic fibrosis. Respiratory Medicine Unit, City Hospital, H.C. Rodgers, A.J. Knox. #ERS Journals Ltd 1999. Hucknall Road, Nottingham, NG5 IPB. ABSTRACT: The electrochemical defect in the bronchial epithelium in cystic fibrosis (CF) consists of defective chloride secretion and excessive sodium reabsorption. The Correspondence: A.J. Knox Respiratory Medicine Unit sodium channel blocker, amiloride, has been shown to reversibly correct the sodium Clinical Sciences Building reabsorption in CF subjects, but long term studies of amiloride have been disap- City Hospital pointing due to its short duration of action. Benzamil, a benzyl substituted amiloride Hucknall Road analogue, has a longer duration of action than amiloride in cultured human nasal Nottingham NG5 lPB epithelium. The results of the first randomized, placebo controlled, double blind, UK crossover study are reported here comparing the effects of benzamil and amiloride on Fax: 0115 9602140 nasal potential difference (nasal PD) in CF. Ten adults with CF attended on three occasions. At each visit baseline nasal PD was Keywords: Amiloride -3 -3 benzamil recorded, the drug (amiloride 1610 M, benzamil 1.7610 M, or 0.9% sodium cystic fibrosis chloride) was administered topically via a nasal spray, and nasal PD was measured at nasal potential difference 15, 30 min, 1, 2, 4 and 8 h.
  • 4 Supplementary File

    4 Supplementary File

    Supplemental Material for High-throughput screening discovers anti-fibrotic properties of Haloperidol by hindering myofibroblast activation Michael Rehman1, Simone Vodret1, Luca Braga2, Corrado Guarnaccia3, Fulvio Celsi4, Giulia Rossetti5, Valentina Martinelli2, Tiziana Battini1, Carlin Long2, Kristina Vukusic1, Tea Kocijan1, Chiara Collesi2,6, Nadja Ring1, Natasa Skoko3, Mauro Giacca2,6, Giannino Del Sal7,8, Marco Confalonieri6, Marcello Raspa9, Alessandro Marcello10, Michael P. Myers11, Sergio Crovella3, Paolo Carloni5, Serena Zacchigna1,6 1Cardiovascular Biology, 2Molecular Medicine, 3Biotechnology Development, 10Molecular Virology, and 11Protein Networks Laboratories, International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano, 34149, Trieste, Italy 4Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy 5Computational Biomedicine Section, Institute of Advanced Simulation IAS-5 and Institute of Neuroscience and Medicine INM-9, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany 6Department of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, Italy 7National Laboratory CIB, Area Science Park Padriciano, Trieste, 34149, Italy 8Department of Life Sciences, University of Trieste, Trieste, 34127, Italy 9Consiglio Nazionale delle Ricerche (IBCN), CNR-Campus International Development (EMMA- INFRAFRONTIER-IMPC), Rome, Italy This PDF file includes: Supplementary Methods Supplementary References Supplementary Figures with legends 1 – 18 Supplementary Tables with legends 1 – 5 Supplementary Movie legends 1, 2 Supplementary Methods Cell culture Primary murine fibroblasts were isolated from skin, lung, kidney and hearts of adult CD1, C57BL/6 or aSMA-RFP/COLL-EGFP mice (1) by mechanical and enzymatic tissue digestion. Briefly, tissue was chopped in small chunks that were digested using a mixture of enzymes (Miltenyi Biotec, 130- 098-305) for 1 hour at 37°C with mechanical dissociation followed by filtration through a 70 µm cell strainer and centrifugation.
  • Documentation for All Data Sets

    Documentation for All Data Sets

    Documentation for all Data Sets HEALTH ABC DATA ANALYSIS FILE....................................................................................... 2 PARTICIPANT HISTORY FILE (PH)............................................................................................. 2 YEAR 10 VISIT DATA (Y10Visit).................................................................................................. 5 YEAR 10 PROXY CONTACT DATA (Y10Proxy)......................................................................... 7 114-month SEMI-ANNUAL TELEPHONE CONTACT DATA (SA114Mo)................................. 9 114-month PROXY CONTACT DATA (SA114Prox)................................................................... 10 MISSED FOLLOW-UP CONTACT DATA (MissVis).................................................................. 11 SPECIAL MISSING VALUE CODES........................................................................................... 13 DROPPED VARIABLES................................................................................................................ 15 LISTINGS ................................................................................................................................ 15 DATA DICTIONARY .................................................................................................................... 16 Appendix I DROPPED VARIABLES AND ALTERNATES ............................................................. 17 Appendix II 114-MONTH CALCULATED VARIABLES................................................................
  • Potassium Channel Blocker Activates Extracellular Signal-Regulated

    Potassium Channel Blocker Activates Extracellular Signal-Regulated

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Journal of the American College of Cardiology Vol. 38, No. 5, 2001 © 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01558-3 Potassium Channel Blocker Activates Extracellular Signal-Regulated Kinases Through Pyk2 and Epidermal Growth Factor Receptor in Rat Cardiomyocytes Satoko Tahara, MD,* Keiichi Fukuda, MD, PHD,† Hiroaki Kodama, MD,* Takahiro Kato, MD,* Shunichiro Miyoshi, MD, PHD,‡ Satoshi Ogawa, MD, PHD* Tokyo, Japan ϩ OBJECTIVES We sought to determine whether potassium (K ) channel blockers (KBs) can activate extracellular signal-regulated kinase (ERK) and to characterize the upstream signals leading to ERK activation in cardiomyocytes. ϩ BACKGROUND Because KBs attenuate K outward current, they may possibly prolong the duration of action ϩ ϩ potentials, leading to an increase in calcium (Ca2 ) transient ([Ca2 ] ) in cardiomyocytes. ϩ i ϩ Elevation of intracellular Ca2 levels can trigger various signaling events. Influx of Ca2 ϩ through L-type Ca2 channels after membrane depolarization induced activation of MEK and ERK through activation of Ras in neurons. Although KBs are frequently used to treat cardiac arrhythmias, their effect on signaling pathways remains unknown. METHODS Primary cultured rat cardiomyocytes were stimulated with four different KBs—4- aminopyridine (4-AP), E-4031, tetra-ethylammonium and quinidine—and phosphorylation of ERK, proline-rich tyrosine kinase 2 (Pyk2) and epidermal growth factor receptor (EGFR) was detected. Action potentials were recorded by use of a conventional microelectrode.
  • 5994392 Tion of Application No. 67375.734 Eb3-1685, PEN. T

    5994392 Tion of Application No. 67375.734 Eb3-1685, PEN. T

    USOO5994392A United States Patent (19) 11 Patent Number: 5,994,392 Shashoua (45) Date of Patent: Nov.30, 1999 54 ANTIPSYCHOTIC PRODRUGS COMPRISING 5,120,760 6/1992 Horrobin ................................. 514/458 AN ANTIPSYCHOTICAGENT COUPLED TO 5,141,958 8/1992 Crozier-Willi et al. ................ 514/558 AN UNSATURATED FATTY ACID 5,216,023 6/1993 Literati et al. .......................... 514/538 5,246,726 9/1993 Horrobin et al. ....................... 424/646 5,516,800 5/1996 Horrobin et al. ....................... 514/560 75 Inventor: Victor E. Shashoua, Brookline, Mass. 5,580,556 12/1996 Horrobin ................................ 424/85.4 73 Assignee: Neuromedica, Inc., Conshohocken, Pa. FOREIGN PATENT DOCUMENTS 30009 6/1981 European Pat. Off.. 21 Appl. No.: 08/462,820 009 1694 10/1983 European Pat. Off.. 22 Filed: Jun. 5, 1995 09 1694 10/1983 European Pat. Off.. 91694 10/1983 European Pat. Off.. Related U.S. Application Data 59-025327 2/1984 Japan. 1153629 6/1989 Japan. 63 Continuation of application No. 08/080,675, Jun. 21, 1993, 1203331 8/1989 Japan. abandoned, which is a continuation of application No. 07/952,191, Sep. 28, 1992, abandoned, which is a continu- (List continued on next page.) ation of application No. 07/577,329, Sep. 4, 1990, aban doned, which is a continuation-in-part of application No. OTHER PUBLICATIONS 07/535,812,tion of application Jun. 11, No. 1990, 67,375.734 abandoned, Eb3-1685, which is a continu-PEN. T. Higuchi et al. 66 Prodrugs as Noye Drug Delivery Sys 4,933,324, which is a continuation-in-part of application No.
  • G Protein-Coupled Receptors

    G Protein-Coupled Receptors

    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
  • Ion Channels

    Ion Channels

    UC Davis UC Davis Previously Published Works Title THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels. Permalink https://escholarship.org/uc/item/1442g5hg Journal British journal of pharmacology, 176 Suppl 1(S1) ISSN 0007-1188 Authors Alexander, Stephen PH Mathie, Alistair Peters, John A et al. Publication Date 2019-12-01 DOI 10.1111/bph.14749 License https://creativecommons.org/licenses/by/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Ion channels. British Journal of Pharmacology (2019) 176, S142–S228 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels Stephen PH Alexander1 , Alistair Mathie2 ,JohnAPeters3 , Emma L Veale2 , Jörg Striessnig4 , Eamonn Kelly5, Jane F Armstrong6 , Elena Faccenda6 ,SimonDHarding6 ,AdamJPawson6 , Joanna L Sharman6 , Christopher Southan6 , Jamie A Davies6 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 3Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 4Pharmacology and Toxicology, Institute of Pharmacy, University of Innsbruck, A-6020 Innsbruck, Austria 5School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 6Centre for Discovery Brain Science, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties.
  • The Role of Intercalated Cell Nedd4–2 in BP Regulation, Ion Transport, and Transporter Expression

    The Role of Intercalated Cell Nedd4–2 in BP Regulation, Ion Transport, and Transporter Expression

    BASIC RESEARCH www.jasn.org The Role of Intercalated Cell Nedd4–2 in BP Regulation, Ion Transport, and Transporter Expression Masayoshi Nanami,1 Truyen D. Pham,1 Young Hee Kim,1 Baoli Yang,2 Roy L. Sutliff,3 Olivier Staub,4,5 Janet D. Klein,1 Karen I. Lopez-Cayuqueo,6,7 Regine Chambrey,8 Annie Y. Park,1 Xiaonan Wang,1 Vladimir Pech,1 Jill W. Verlander,9 and Susan M. Wall1,10 Due to the number of contributing authors, the affiliations are listed at the end of this article. ABSTRACT Background Nedd4–2 is an E3 ubiquitin-protein ligase that associates with transport proteins, causing their ubiquitylation, and then internalization and degradation. Previous research has suggested a corre- lation between Nedd4–2 and BP. In this study, we explored the effect of intercalated cell (IC) Nedd4–2 gene ablation on IC transporter abundance and function and on BP. Methods We generated IC Nedd4–2 knockout mice using Cre-lox technology and produced global pen- 2/2 drin/Nedd4–2 null mice by breeding global Nedd4–2 null (Nedd4–2 ) mice with global pendrin null 2/2 (Slc26a4 ) mice. Mice ate a diet with 1%–4% NaCl; BP was measured by tail cuff and radiotelemetry. We 2 measured transepithelial transport of Cl and total CO2 and transepithelial voltage in cortical collecting ducts perfused in vitro. Transporter abundance was detected with immunoblots, immunohistochemistry, and immunogold cytochemistry. 2 2 Results IC Nedd4–2 gene ablation markedly increased electroneutral Cl /HCO3 exchange in the cortical col- lecting duct, although benzamil-, thiazide-, and bafilomycin-sensitive ion flux changed very little.
  • GPCR/G Protein

    GPCR/G Protein

    Inhibitors, Agonists, Screening Libraries www.MedChemExpress.com GPCR/G Protein G Protein Coupled Receptors (GPCRs) perceive many extracellular signals and transduce them to heterotrimeric G proteins, which further transduce these signals intracellular to appropriate downstream effectors and thereby play an important role in various signaling pathways. G proteins are specialized proteins with the ability to bind the nucleotides guanosine triphosphate (GTP) and guanosine diphosphate (GDP). In unstimulated cells, the state of G alpha is defined by its interaction with GDP, G beta-gamma, and a GPCR. Upon receptor stimulation by a ligand, G alpha dissociates from the receptor and G beta-gamma, and GTP is exchanged for the bound GDP, which leads to G alpha activation. G alpha then goes on to activate other molecules in the cell. These effects include activating the MAPK and PI3K pathways, as well as inhibition of the Na+/H+ exchanger in the plasma membrane, and the lowering of intracellular Ca2+ levels. Most human GPCRs can be grouped into five main families named; Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2, and Secretin, forming the GRAFS classification system. A series of studies showed that aberrant GPCR Signaling including those for GPCR-PCa, PSGR2, CaSR, GPR30, and GPR39 are associated with tumorigenesis or metastasis, thus interfering with these receptors and their downstream targets might provide an opportunity for the development of new strategies for cancer diagnosis, prevention and treatment. At present, modulators of GPCRs form a key area for the pharmaceutical industry, representing approximately 27% of all FDA-approved drugs. References: [1] Moreira IS. Biochim Biophys Acta. 2014 Jan;1840(1):16-33.
  • Investigating Neuroprotectants for the Treatment of Chemotherapy-Induced Peripheral Neuropathy

    Investigating Neuroprotectants for the Treatment of Chemotherapy-Induced Peripheral Neuropathy

    THE UNIVERSITY OF NEW SOUTH WALES Translational Neuroscience Facility School of Medical Sciences Faculty of Medicine UNSW Australia A thesis in fulfilment of the requirements for the degree of: Masters Investigating Neuroprotectants for the Treatment of Chemotherapy-Induced Peripheral Neuropathy by Munawwar Abdulla Supervisor: Dr. Gila Moalem-Taylor Co-supervisor: Dr. Justin Lees Co-supervisor: Dr. Patsie Pollie August, 2018 i The University of New South Wales Thesis/Dissertation Sheet Surname or Family name: Abdulla First name/s: Munawwar Abbreviation for degree as given in the University calendar: MSc School: School of Medical Sciences Faculty: Medicine Title: Investigating neuroprotectants for the treatment of chemotherapy-induced peripheral neuropathy Abstract 350 words maximum: Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and dose-limiting side effect of many chemotherapy regimens and is becoming a more prevalent issue as the longevity of cancer patients continues to increase. Sensory symptoms include neuropathic pain, paraesthesia, and numbness and usually spread in a glove-and-stocking distribution. At present, there are no effective medications to treat or prevent CIPN, and the mechanisms by which symptoms are induced have not been fully elucidated. Paclitaxel (PTX) is a commonly used chemotherapeutic that induces neuropathy in a high percentage of patients. The broad aim of this thesis was to establish a model of CIPN in vitro and in vivo and test clinically approved drugs for potential neuroprotective effects. Since the dorsal root ganglion (DRG) has been implicated in CIPN, we cultured dissociated primary DRG neurons from 5-week-old C57BL/6 mice and treated them with PTX to observe neurotoxic effects.
  • Characterization of Na+ Transport Across the Cell Membranes of the Was Actively Reabsorbed in This Segment [61

    Characterization of Na+ Transport Across the Cell Membranes of the Was Actively Reabsorbed in This Segment [61

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Kidney Internationa4 VoL 47 (1995), pp. 789—794 Characterization of Na transport across the cell membranes of the ascending thin limb of Henle's loop NOBUYUKI TMcAIsHI, YOSHIAKI KONDO, IKUMA FuJIwA1tzi, OSAMU ITO, YUTAKA IGARASHI, and KEISHI ABE Department of Clinical Biology and Hormonal Regulation, Department of Pediatrics, and The Second Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan Characterization of Na+ transport across the cell membranes of the was actively reabsorbed in this segment [61. Later in vivo studies ascending thin limb of Henle's loop. In the ascending thin limb of Henle's using electrodes with increased reliability found a lumen-positive loop (ATL), intracellular Nat is extruded by Nat/KtATPase in the basolateral membrane. To further characterize Nat transport across the Vt under free-flow conditions in the ATE [3—71, but did not cell membranes of the ATL, the intracellular sodium concentrationresolve the issue of whether active Cl reabsorption was respon- ([Nat];) was monitored using a sodium-sensitive fluorescent probe, SBFI, sible for lumen-positive potentials. In vitro studies demonstrated in the in vitro microperfused hamster ATE Basal [Nat]1 was 19.0 1.2 the absence of active NaCl reabsorption in the Alt and found no mM (N =24).Removal and replacement of luminal Nat did not change [Nat]1 in the presence of Nat in the bathing fluid. In contrast, luminal evidence for a spontaneous Vt or net reabsorption of NaCl Nat removal reduced [Nat]1 from 11.6 0.9 to 6.3 0.8 m in the[8—101.